Utama › Kanser (semua jenis) › Oklahoma
Kajian klinikal Kanser (semua jenis) di Oklahoma
15 kajian untuk Kanser (semua jenis) sedang mencari peserta di lokasi di Oklahoma.
Bandar di Oklahoma
Teks kajian rasmi (Bahasa Inggeris)
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 1 Okt 2026 · NCT07024784Registry Study for Radiation Therapy Outcomes
- Oklahoma Proton Center, Oklahoma City
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 29 Sep 2026 · NCT01255748Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551Prospective Study to Assess a Diagnostic Aid for Cancer
- Hightower Clinical, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 45 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07046260Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 2/3
Semua umur · Semua jantina · Dikemas kini 18 Sep 2026 · NCT03435796A Phase 1/1b Study of IAM1363 in HER2 Cancers
- OU Health Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06253871Project: Every Child for Younger Patients With Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
Mengambil pesertaKajian pemerhatian
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06580314Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07327489GEMINI-NSCLC: NSCLC Biomarker Study
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Feb 2026 · NCT05236114Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Oklahoma University Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Nov 2025 · NCT05997017SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT05107674Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2025 · NCT05234177Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- OUHSC Stephenson Cancer Center, Oklahoma City
- Mercy Health Center - Oncology Hematology, Oklahoma City
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Nov 2024 · NCT03860883Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.